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a b s t r a c t
The systematic use of antivitamin K anticoagulants (AVK) as rodenticides caused the selection of rats
resistant to AVKs. The resistance is mainly associated to genetic polymorphisms in the Vkorc1 gene
encoding the VKORC1 enzyme responsible for the reduction of vitamin K 2,3-epoxide to vitamin K. Five
major mutations, which are responsible for AVK resistance, have been described. Possible explanations
for the biological cost of these mutations have been suggested. This biological cost might be linked
to an increase in the vitamin K requirements. To analyze the possible involvement of VKORC1 in this
biological cost, rVKORC1 and its major mutants were expressed in Pichia pastoris as membrane-bound
proteins and their catalytic properties were determined for vitamin K and 3-OH-vitamin K production.
In this report, we showed that mutations at Leu-120 and Tyr-139 dramatically affect the vitamin K
epoxide reductase activity. Moreover, this study allowed the detection of an additional production of
3-hydroxyvitamin K for all themutants in position 139. This result suggests the involvement of Tyr-139
residue in the second half-step of the catalyticmechanism corresponding to the dehydration of vitamin
K epoxide. As a consequence, the biological cost observed in Y139C and Y139S resistant rat strains is at
least partially explained by the catalytic properties of the mutated VKORC1 involving a loss of vitamin
K from the vitamin K cycle through the formation of 3-hydroxyvitamin K and a very low catalytic
efﬁciency of the VKOR activity.
C© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY-NC-ND license.. Introduction
The systematic use of antivitamin K anticoagulants (AVK) as ro-
enticides since 50 years caused the selection of Rattus norvegicus rats
esistant to AVKs [1,2]. This resistance is foundworldwide and is sup-
orted by twomajormechanisms in rats 1/ an accelerated detoxiﬁca-
ion system involving cytochrome P-450 [3,4] and 2/ the inefﬁciency
f AVKs on VKORC1, their molecular target. This last mechanism has
een observed in numerous countries but appears to be major in
estern Europe, even if cohabitation of these two mechanisms had
een demonstrated in Denmark [5].Abbreviations: AVK, antivitamin K anticoagulant; VKORC1, vitamin K epoxide re-
uctase; vit K, vitamin K; vit K>O, vitamin K2,3-epoxide; OH-vit K, hydroxyvitamin K;
it KH2, vitamin K hydroquinone; VKDP, vitamin K-dependent protein.
* Corresponding author. Address: USC 1233 INRA-Vetagro Sup, 1 avenue Bourgelat,
9280 Marcy l’Etoile, France. Tel.: +33 (0)4 78 44 24 11; fax: +33 (0)4 78 87 05 16.
E-mail address: virginie.lattard@vetagro-sup.fr (V. Lattard).
211-5463 c© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europe
ttp://dx.doi.org/10.1016/j.fob.2013.02.001The Vkorc1 gene encodes the vitamin K epoxide reductase
(VKORC1) [6,7]. This enzyme is responsible for reducing vitamin K-
2,3-epoxide (vit K>O) to the enzymatically activated form, the vita-
min K hydroquinone (KH2). This reaction is the limiting step of the
recycling of vitaminK [8]. KH2 is a cosubstrate for carboxylation of the
vitamin K-dependent proteins (VKDP) including four clotting factors
(II, VII, IX, X). Post-translational modiﬁcation of glutamate to gamma
carboxyl glutamate is required for the activity of VKDP. Inhibition
of VKORC1 by AVK results in partially under-carboxylated vitamin
K-dependent blood clotting factors and thus in severe bleeding prob-
lems.
In Western Europe, ﬁve major mutations in Vkorc1 (i.e., L120Q,
L128Q, Y139C, Y139F, Y139S) which were shown to be responsible
for the resistance to AVKs [9–12] (Table 1) have been observed in
large geographical areas [1,2]. L128Qmutationwas found in Scotland,
L120Q in Hampshire and Berkshire, Y139S in Wales, Y139F in France
and Belgium and Y139C in Denmark and Germany. The spreading of
the resistance in wild rodent populations depends on the beneﬁt due
to the mutations in the presence of the selection pressure (i.e., a ro-
denticide treatment with AVKs) and on the potential biological costan Biochemical Societies. Open access under CC BY-NC-ND license.
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Table 1
Ki values for recombinantmutated rVKORC1enzymes towardwarfarin (ﬁrst generation
AVK) and difenacoum (second generation AVK), previously reported by Hodroge et al.
[12]. These AVKs inhibited VKOR activity in a non-competitive manner
Protein Warfarin (μM) Difenacoum (μM)
rVKORC1 0.5 0.03
L120Q >100 0.89
L128Q 4.0 0.07
Y139C >100 0.16
Y139F >100 0.10
Y139S >100 0.09associated to the mutation in the absence of the selection pressure.
Such a biological cost associated to Vkorc1 mutations could provoke
a decrease in the allelic frequency of resistance alleles in the absence
of AVK treatment. Yet the in vivo studies suggested a negative effect
of Vkorc1mutations on the vitamin K recycling leading to an increase
in the vit K requirements. The homozygous Welsh resistant rats had
a 20-fold increase in vit K requirements compared to susceptible rats
[13] while the increased vit K requirements of the homozygous Scot-
tish rats has been reported intermediate compared with that in ho-
mozygous Welsh rats [14,15]. For the Danish/German resistant rats,
various studies reported also an increase in the vit K requirements.
Nevertheless, depending on the studies, this increase requirement
was moderate to severe [14–16]. Moreover, various ﬁtness trade-offs
associatedwith AVKs resistancewere described in rats. In some resis-
tant rats, retarded growth [16,17], modiﬁcation of the reproductive
capacities [18,19] vascular calciﬁcation [20]were observed associated
to the resistance to AVKs.
The objective of this workwas to study the involvement of the dif-
ferentmutations of Vkorc1 in the biological cost speciﬁcally described
in various strains of wild rats resistant to AVKs. To analyze the causes
of an increase in the vit K requirements, we analyzed in this study the
catalytic properties of the wild type and mutated VKORC1 and linked
these properties to such ﬁtness outcomes observed in the different
strains of resistant rats.
2. Materials and methods
2.1. Chemicals
Vit K1 was purchased fromSigma–Aldrich (SaintQuentin Fallavier,
France). Vit K1 (Phylloquinone) was converted to vit K1>O according
to [32]. 2-OH-vit K1 and 3-OH-vit K1 were synthesized from vit K1>O
according to [22]. Methanol HPLC grade, and acetic acid (analysis
grade) were obtained from Merck (Germany).
2.2. Heterologous expression of recombinant rVKORC1 proteins
Recombinant rVKORC1 and its ﬁve major mutants were ex-
pressed in Pichia pastoris and yeast microsomes preparations were
performed as previously described [12]. Expression level quantiﬁ-
cation of VKORC1 proteins were determined by Western blotting,
as described previously [21]. Microsomal proteins were separated
on 12% SDS–polyacrylamide gel electrophoresis, transferred onto
Immobilon-Pmembranes and probedwith anti-c-myc antibodies (In-
vitrogen, Cergy Pontoise, France). The resulting immunocomplexes
were visualized using alkaline phosphatase-conjugated anti-mouse
immunoglobulins as secondary antibodies and a BCIP/NBT solution.
Quantiﬁcation of the stained bands was performed by densitome-
try using the Scion Image software. The relative intensity (RI) of the
signal was correlated to the quantity of microsomal proteins. The re-
lation was linear from 0 to 50 μg for microsomal proteins containing
WT-VKORC1 or mutated VKORC1. To evaluate the expression level of
VKORC1 proteins, the expression of wild type VKORC1 (WT-VKORC1)was designated as the basal expression. For the quantiﬁcation of all
the mutants, the same unique pool of yeast microsomes containing
WT-VKORC1 was used. Therefore, its expression factor was by deﬁ-
nition 1. The expression level of the mutated VKORC1 was evaluated
by comparison to the expression of WT-VKORC1. For this purpose,
various amounts (from 0 to 50 μg) of microsomal proteins contain-
ing WT-VKORC1 and various amounts (depending on the expression
level) of microsomal proteins containing one of the mutated VKORC1
were analyzed on the same western blot. Two linear relations (RI
= a × quantity of microsomes loaded) were obtained, the ﬁrst one
for microsomes containing WT-VKORC1 (characterized by a speciﬁc
slope aWT), the second one for microsomes containing the mutated
VKORC1 (characterized by a slope amut). Ratio amut/aWT allowed us to
determine the expression factor characterizing the expression level
of the mutated VKORC1 in the microsomal fraction compared to the
expression level of the WT-VKORC1.
2.3. Vitamin K epoxide reductase activity assays
Microsomal VKOR activity was assayed as previously described.
Brieﬂy, standard reactions were performed in 200 mM Hepes buffer
(pH 7.4) containing 150 mM KCl, 1 mM dithiothreitol, 0.75–2 g L−1
of yeast microsomal proteins containing recombinant VKORC1 or 1 g
L−1 of rat liver microsomal proteins. The reaction was started by the
addition of vit K1>O solution in 1% Triton X-100. After incubation at
37 ◦C for 30 min, the reaction was stopped by adding of 4 mL of iced
1:1 isopropanol/hexane solution. After centrifugation at 5000g for 10
min, the hexane layer was removed and dried under nitrogen. The
dry residue was dissolved in 0.2 mL of isopropanol.
2.4. Chromatography
The Agilent 1200 HPLC was equipped with a SunFire reversed-
phase C8 column (4.6 mm × 150 mm, 5 μm, Waters, Milford, MA,
USA). The mobile phase was a mixture of 1‰ acetic acid in water (A)
and 1‰ acetic acid in methanol (B) with gradients programmed as
follows: initial 7% A maintained for 1 min, decreased to 2.5% A in 7
min. The ﬂow ratewas 1mL/min. The column temperaturewas 45 ◦C.
The injection volumewas 20 μL. The temperature of the autosampler
traywas set to 5 ◦C and the sampleswere protected from the daylight.
The efﬂuent from the LC column was diverted to waste for the ﬁrst
1.5 min after the injection to avoid contamination with non-volatile
salts and background interferences.
2.5. Ion trap mass spectrometry
The LC/MS/MS experiment was performed on a 1100 Series LC/
MSD ion Trap VL with an atmospheric pressure chemical ionisation
(APCI) interface and a LCMS Chemstation software fromAgilent Tech-
nologies (Palo Alto, CA, USA). The ionization mode was positive. The
interface and MSD were as follows: nebulizer pressure, 60 psi (N2);
dry gas, 5 L/min (N2); dry gas temperature, 350 ◦C; spray capillary
voltage, 4000 V; corona needle, 4000 nA; collision-induced dissocia-
tion, 1 V. Collision gas in the trap was helium with a pressure of 6 ×
10−6 mbar.
2.6. Kinetics
Kinetic parameters (Km and Vmax) were obtained from at least
two separate experiments after the addition of increasing amounts
of vit K>O (0.003–0.2 mM) to the standard reaction. The estima-
tion of the kinetic parameters was achieved by the incubation of at
least nine different concentrations of vit K>O. Incubations were per-
formed in duplicate. Data were ﬁtted by nonlinear regression using
theMichaelis–Mentenmodel using the curveﬁtterR-ﬁt program[33].
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Fig. 1. Semi-quantitative analysis ofwild type ormutatedVKORC1proteins abundance
in yeast microsomes after normalization of the expression of recombinant proteins in
the microsomal fractions by western blot. Various amounts of microsomal proteins
were loaded in order to obtain the same detected signal.
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Fig. 2. Chemical structure of 2- OH-vit K1 and 3-OH-vit K1 and MS2 spectrum of 2-
and 3-OH-vit K1 (c). MS2 data were obtained from the 469,2 m/z ion as the precursor
for collision-induced dissociation.
Fig. 3. Chromatograms of 2- and 3-OH-vit K1 (a), vit K1 (b) and vit K1>O (c) chemical
standards.. Results
.1. Expression of recombinant mutant rVKORC1 proteins
To assess the functional properties of the wild type rVKORC1 and
ts ﬁve major spontaneous mutants (L120Q-, L128Q-, Y139C-, Y139F-
nd Y139S-rVKORC1) detected in wild rats resistant to AVKs inWest-
rn Europe, these proteins were overexpressed as c-myc-fused pro-
eins in P. pastoris. All the mutated proteins were expressed in the
icrosomal fraction with an expected molecular mass of approxi-
ately 20 kDa. Depending on the mutation, the levels of expression
f the recombinant protein in themicrosomal fractionwere different.
hus, we monitored the expression level of each mutated protein by
estern blot analysis, as described previously [21] and the level of
xpression was comprised between 1 and 10 (Fig. 1).
.2. Mass spectral properties of vit K1, vit K1>O, 2-OH-vit K1 and
-OH-vit K1
To investigate the formation of OH-vit K by the recombinant
VKORC1 proteins, we established an LC–MS/MS-based method al-
owing the detection of 2-OH-vit K1, 3-OH-vit K1, vit K1>O and vit
1. Therefore, the chromatographic conditions previously described
y Hodroge et al. [12,21] allowing the detection of vit K1 and vit
1>O only were slightly modiﬁed. Under the new chromatographic
onditions, the protonated 2-OH-vit K1 (m/z 469) and 3-OH-vit K1
m/z 469) molecules obtained by chemical synthesis as described by
22] were detected, respectively, at 3.7 and 5.2 min (data not shown).
heMS2 spectra of the 2-OH-vit K1 or 3-OH-vit K1 469molecular ions
ere identical and showedmainly one fragment ion atm/z 451 (−18)
ttributed to the loss of H2O (Fig. 2). For all the analyses performed in
his study, identiﬁcation criteria for 2-OH-vit K1 were the retention
ime at 3.7 min and the product ion 469>451 (m/z(+) = 451); iden-
iﬁcation criteria for 3-OH-vit K1 were the retention time at 5.2 min
nd the product ion 469>451 (m/z(+) = 451) (Fig. 3). Under the new
hromatographic conditions, the product ion from vit K1>O 467>307
m/z) and the product ion from vit K1 451>187 (m/z) identiﬁed pre-
iously [12,21] were detected, respectively, at 7.1 and 8.2 min. For vit
1, 2-OH-vit K1 and 3-OH-vit K1, linearity and accuracy were tested
rom 25 to 2000 ng/mL (n = 20). The response was linear throughout
he concentration range tested with a coefﬁcient of correlation (r2)
bove 0.99. Accuracy was between 80% and 120% of the theoretical
oncentrations.
.3. Production of vit K by recombinant mutant rVKORC1 proteins
Recombinant wild type rVKORC1 and its ﬁve major mutants were
ll able to reduce vit K1>O to vit K. The reaction rates of recom-
inant wild type or mutated rVKORC1 towards vit K1>O followed
he Michaelis–Menten model allowing the determination of kinetic
arameters (Table 2). Vmax values indicated in this table are Vmax cal-
ulated after normalization using the expression factor determined
reviously by immunoblot analysis. The Km values of recombinant
120Q-, L128Q-, Y139F- and Y139S-rVKORC1 were similar to that ofthe recombinant WT-rVKORC1. Only the Km of Y139C-rVKORC1 was
signiﬁcantly higher (8-fold) to that ofWT-rVKORC1, whereas its Vmax
valuewasunmodiﬁed.On the contrary, theVmax value of recombinant
L120Q-, Y139F- and Y139S-rVKORC1 were 5, 2.5 and 5.5-fold lower
than that of WT- rVLORC1, respectively.
3.4. Production of OH-vit K by recombinant mutant rVKORC1 proteins
Because the formation of OH-vit K from vit K>O in the presence of
rat liver microsomes was previously described, we analyzed the in-
volvement of the wild type and mutant rVKORC1 in this production.
We beforehand veriﬁed that our standard incubation performed in
the absence of substrate (i.e., vit K1>O) or in the presence of micro-
somal proteins of non-recombinant yeasts or when incubation time
was 0 min did not result in a production of 2-OH-vit K1 or 3-OH-vit
K1. To investigate the VKORC1-dependent production of OH-vit K, the
formation of these products after incubation of 200 μM of vit K1>O
was evaluated in the presence of recombinant wild type or mutant
rVKORC1. When incubation was performed in the presence of WT-
rVKORC1 or L120Q- or L128Q-rVKORC1, virtually no 2-OH-vit K1 or
3-OH-vit K1 was detected but vit K1 was found as described previ-
ously (Fig. 4a). When incubation of vit K1>O was performed in the
presence of Y139C-, Y139F-, or Y139S-rVKORC1, two different reac-
tion productswere detected, corresponding, respectively, to 3-OH-vit
K1 and vit K1 (Fig. 4b). Formation of 2-OH-vit K1 was not detected for
rVKORC1 mutated in position 139. The 3-OH-vit K1 production in
the presence of Y139C-, Y139F-, or Y139S-rVKORC1 was linear ac-
cording to the incubation time and to the concentration of proteins
(data not shown). The reaction rates of recombinant rVKORC1 mu-
tated in position 139 for the production of 3-OH-vit K1 followed the
Michaelis–Menten model allowing the determination of kinetic pa-
rameters (Table 2). The Km values of recombinant Y139C-, Y139F- and
Y139S-rVKORC1 evaluated for the production of 3-OH-vit K1 were
identical to those determined for the production of vit K1. The Vmax
Benjamin Matagrin et al. / FEBS Open Bio 3 (2013) 144–150 147
Table 2
Catalytic properties of wild type andmutated rVKORC1. To determine the VKOR activity and the production of OH-vit K, standard reactionswere performed in 200mMHepes buffer
(pH 7.4) containing 150 mM KCl and 0.75–2 g L−1 of microsomal proteins containing membrane wild type or mutant VKORC1. Kinetic parameters (Km, Vmax and Vmax/Km) of the vit
K or 3-OH-vit K production were evaluated by incubation of increasing concentrations of vit K>O (from 0 to 200 μM). The Vmax values determined at saturating concentration of vit
>O substrate were evaluated after normalization of the VKORC1 expression. Each data point represents the mean ± 2SD of three individual determinations. *p < 0.02 compared
to VKORC1.
Recombinant
proteins Production of vit K Production of 3-OH-vit K V vit Kmax /V
3−OH−vit K
max
Km (μM)
Vmax (pmol/
min/mg)
Vmax/Km
(nL/min/mg)
Vmax/Km
(%/WT) Km (μM)
Vmax (pmol/
min/mg)
Vmax/Km
(nL/min/mg)
WT 7.2 ± 2.5 11.6 ± 0.6 1611 100 – <0.08 – >145
L120Q 25.0 ± 4.0 0.9 ± 0.01* 36 2.2 – <0.08 – >10
L128Q 12.1 ± 1.0 9.6 ± 1.0 793 49 – 0.13 ± 0.02 10.7 73
Y139C 60.0 ± 6.0* 5.1 ± 0.3 85 5.3 57.6 ± 3.0 3.90 ± 0.80* 65.0 1.3
Y139F 17.8 ± 4.5 1.9 ± 0.2* 107 6.6 23.1 ± 4.7 0.63 ± 0.09* 35.4 3.0
Y139S 13.1 ± 1.3 0.8 ± 0.1* 61 3.8 19.5 ± 2.5 0.98 ± 0.09* 74.8 0.8
Fig. 4. Chromatograms obtained after analysis of the incubation of vit K1>O with wild type rVKORC1 (a1) or Y139C-rVKORC1 (b1) and their respective MS2 spectrums (a2 and
b2) obtained from the 469,2 m/z ion as the precursor for collision-induced dissociation. Microsomal proteins of P. pastoris yeast cells expressing the recombinant enzyme were
incubated in the presence of 200 μM of vit K>O as described under Materials and Methods. Retention times for 2-OH-vit K1, 3-OH-vit K1, vit K1>O and vit K1 were, respectively,
3.5, 5.2, 7.1 and 8.2 min.
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Fig. 5. Production of vit K and 3-OH-vit K by liver microsomes from susceptible rats,
from rats homozygous for Y139F and from rats homozygous for Y139C incubated in
the presence of 200 μM of vit K1>O.
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pectively 3.9, 0.6 and 1.0 pmol/min/mg (i.e., corresponding to∼80%,
0%and120%of theproductionof vitK1 in the sameconditions) (Table
). The production of 3-OH-vit K1 catalyzed by rVKORC1 mutated in
osition 139 was inhibited in a non-competitive manner by difena-
oum, an antivitamin K molecule, with a Ki similar to that obtained
or the production of vit K1 (Table 1) [12].
.5. Production of vit K and OH-vit K by rat liver microsomes
In order to compare the properties of recombinant rVKORC1 pro-
eins with those of the native VKORC1, we evaluated the production
f vit K and OH-vit K in the presence of 200 μM of vit K1>O by liver
icrosomes from susceptible rats, from rats homozygous for Y139F
nd from rats homozygous for Y139C. Results obtained are presented
n Fig. 5. The production of vit K1 from vit K1>O was observed for
ll rat liver microsomes (Fig. 5). Production of vit K1 for liver micro-
omes from rat homozygous for Y139C and from rat homozygous for
139Fwas, respectively,∼3- and 6-fold lower. For all the rat livermi-
rosomes used in this study, the production of 2-OH-vit K1 from vit
1>O was never detected. Production of 3-OH-vit K1 was observed
nly in the presence of liver microsomes from rats homozygous for
139C or for Y139F (Fig. 5). Production of 3-OH-vit K1 for liver micro-
omes from rat homozygous for Y139C and from rat homozygous for
139F corresponded, respectively, to∼ 50% and 28% of the production
f vit K1 in the same conditions.
. Discussion
In 1983, Fasco et al. [22] observed an in vitro warfarin-dependent
roduction of OH-vit K in rat liver microsomes incubated in the pres-
nce of vit K>O. This production was only observed with warfarin-
esistant rat liver microsomes, not with those from normal rats. They
uggested that this warfarin-dependent production is catalyzed by
KOR. Nevertheless, they failed to demonstrate in vivo the involve-
ent of VKOR activity in this production [23] and they were not able
o explain the association between this production and the resistance
o AVK, especially since the cause of the resistance of the rats used in
his study was at that time unknown [22,23]. Therefore we expressed
erein the wild type rVKORC1 and its ﬁve major spontaneous mu-
ants associated to the resistance to AVK in Rattus norvegicus [1,2]
nd determined the functional consequences of these mutations on
he recycling of vit K.We considered in this study the production of vit
catalyzed by VKORC1, but also the production of the metabolically
nactive 2- or 3-OH-vit K.
In this study, we demonstrate the role of VKORC1 in the synthesis
f OH-vit K. When standard incubations of vit K>O was performedin the presence of liver microsomes of rat homozygous for Y139F or
recombinant VKORC1 enzymes mutated in position 139 (i.e., Y139C-,
Y139F- and Y139S-rVKORC1), a second metabolite, in addition to vit
K, was detected. The identiﬁcation criteria of this second metabolite
coincided totally with those of the 3-OH-vit K chemical standard. No
OH-vit K formation was observed in incubations using liver micro-
somes from susceptible rats as previously described by Fasco et al.
[22], and also in incubations using recombinant wild type-rVKORC1
and recombinant L120Q- and L128Q-rVKORC1. Because wild-type-,
L120Q- and L128Q-rVKORC1 do not catalyze the production of OH-
vit K from vit K>O, it appears that it is the absence of the Tyr-139
residue which leads to the production of 3-OH-vit K, in addition to
the production of vit K.
To further explore the mechanism of the production of 3-OH-vit
K, we determined the kinetic constants characterizing the production
of 3-OH-vit K comparatively to those obtained for the production of
vit K. For all the recombinant rVKORC1 mutated in position 139, Km
obtained for the production of 3-OH-vit K is similar to that obtained
for the parallel production of vit K. Similarity of Km between 3-OH-vit
K and vit K productions suggests that the binding site of vit K>O is
similar whatever is the reaction product formed by VKORC1. Another
argument is the fact that the production of 3-OH-vit K is inhibited by
AVK (i.e., difenacoum) in a non-competitive manner similarly to the
production of vit K with the same inhibition constant [9,12]. There-
fore, it is more likely that the production of 3-OH-vit K is due to
a modiﬁcation of the reaction mechanism than to a non-enzymatic
conversion of the free enolate as proposed by Fasco et al. [22]. A the-
oretical reaction mechanism for converting vit K>O to vit K by VKOR
was proposed in 1981 by Silverman [24] based on a chemical model
study. This mechanism was revisited later by a quantum chemical
study [25]. The theoretical model implied an active site composed of
two Cys (i.e., Cys 132 and 135 of the CXXC motif) and can be decom-
posed into two half-steps (Fig. 6). The ﬁrst half-step corresponds to
the formation of a covalent bond between one of the catalytic Cys132
or 135 and the C2 of vit K>O. The second half-step allows the dehy-
dration of the substrate and the liberation of the reaction product. It
implies the intervention of the second Cys and leads to the formation
of a disulﬁde bridge between the two Cys. The production of 3-OH-
vit K by VKORC1 is of particular interest because it demonstrates
the crucial role of the Tyr-139 amino acid in this reaction mecha-
nism. Tyr-139 residue appears to determine the second half-step of
the catalytic mechanism (Fig. 6). Indeed, in the absence of Tyr-139,
the second half-step is clearly modiﬁed in favour of the formation of
3-OH-vit K. The phenolic alcool of Tyr-139 could be involved in the
protonation of the hydroxyl group linked to the C3of the intermediate
produced by the ﬁrst half step of the catalysis (Fig. 6). In the absence of
Tyr-139, another proton, possibly from the medium, should be used
in order to produce the vit K but, the formation of 3-OH-vit K, which
does not involve such a protonation, is favoured. As a consequence
the exchange of proton in which the Tyr-139 is involved is slowed
down when Tyr-139 residue is mutated and the production of vit K
by the mutated VKORC1 is decreased.
Because of this additional pathway for vit K>O, the vitamin K sta-
tus is thus determined by the ability of VKORC1 to reduce vit K>O to
vit K, by the abnormal ability of VKORC1 to produce OH-vit K leading
to a leak of vit K from its own cycle, and ﬁnally by the food input
(Fig. 7). It is thus conceivable that a decrease in the VKOR catalytic
efﬁciency (as observed for L120Q, Y139C/F/C) associated or not with
an elevated 3-OH-vit K production (as observed for mutations in po-
sition 139) might cause an increase in dietary requirements of vit K.
Indeed, severe increase in dietary requirements was described in re-
sistant rats from Denmark and Germany (i.e., certainly homozygous
for Y139C) [16,19] and from Wales (i.e., certainly homozygous for
Y139S) [26]. On the contrary, vit K requirements in resistant rats from
Scotland (i.e., homozygous for L128Q) [27] are described to be similar
to vit K requirements of susceptible rats. All these observations are
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Fig. 6. Mechanism for OH-vit K formation by Y139C, Y139F or Y139S.
Fig. 7. The vitamin K cycle and the speciﬁc loss of vit K by the formation of 3-OH-vit K
catalyzed by Y139C, Y139F or Y139S.totally in agreement with the catalytic results obtained in this study.
Furthermore, in rat homozygous for Y139C, retarded growth [16,17]
and cardiovascular calciﬁcations [19] were reported. Both are to be
considered as the consequence of a deﬁciency in vit K. Indeed, Ma-
trix Gla protein (MGP), a VKDP which is considered as an inhibitor
of the tissue calciﬁcation, is effective under its gamma-carboxylated
form only [28,29]. When gamma-carboxylation reaction is stopped
due to the decrease in the efﬁciency of the vitamin K cycle (as it is
demonstrated for Y139C), MGP is probably undercarboxylated. The
presence of undercarboxylated MGP might explain the cardiovascu-
lar phenotype observed in Y139C rats [20] and the retarded growth[16,17] associated probably to growth plate closure with excessive
mineralization as described for rats treated with warfarin [30]. The
absence of such clinical signs in rats homozygous for L120Q argues for
a major involvement of the loss of vit K in the vitamin K cycle by the
formation of 3-OH-vit K and a minor involvement of the low VKOR
activity in the biological cost. Therefore, resistance to AVKs would
not be systematically associatedwith a biological cost. Only the resis-
tance due to a mutation of the Tyr-139 residue might be associated
with a biological cost. Such a mutation was described in one human
patient requiring a high dose of a vit K antagonist [31]. In this patient,
the Tyr-139 residue is replaced by a His residue [31]. This mutation
was demonstrated to lead to resistance to AVKwithoutmodifying the
catalytic efﬁciency to produce vit K [21]. On the other hand the con-
sequences of this mutation on the production of OH-vit K were not
analyzed. It would be interesting to evaluate the OH-vit K formation
in patients carriers for this mutation and the clinical consequences
associated with such a mutation.
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